Previous 10 | Next 10 |
Enovis ( NYSE: ENOV ) said it launched its FDA-cleared augmented reality (AR) surgical guidance system ARVIS. The company added that ARVIS (Augmented Reality Visualization and Information System) was engineered for orthopedic surgeons so they can visualize precisi...
ARVIS offers orthopedic surgeons a wearable AR headset used during surgery to help accurately place hip and knee implants Today, Enovis (NYSE: ENOV), an innovation-driven medical technology company, announced the commercial launch of ARVIS ® (Augmented Reality V...
Wilmington, DE, July 12, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2022 financial results on Thursday, Augu...
WILMINGTON, DE, July 06, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, announced that it has acquired Insight Medical Systems, a technology company dedicated to reimagining orthopedic surgical guidance. Insight ...
Enovis ( NYSE: ENOV ) announced that Ben Berry, CFO, will succeed Chris Hix as CFO, effective Jan.1, 2023; Mr. Hix is in role since 2016. Mr. Hix will transition to an advisory role until his retirement in Q4 of 2023. Mr. Berry h...
Wilmington, DE, June 30, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced that Ben Berry, CFO of the Company’s business units, will succeed Chris Hix as Chief Financial Officer, effective January 1, 2023...
Jeff Smith’s 13F portfolio value increased from $7.22B to $7.54B this quarter. Starboard Value added Humana, Mercury Systems, Kohl's, and LivePerson while decreasing Corteva and ACI Worldwide. The largest three individual stock positions are GoDaddy, Huntsman, and AECOM. Th...
Argus Research has started Enovis Corp. (NYSE:ENOV) with a hold rating as it has concerns about EPS growth and "steep competition" from medical device peers. The firm does not have a price target. Analyst John Eade said that Enovis' record on EPS growth is not as strong as rivals, adding that...
A comprehensive ankle plating portfolio, designed with the proven technology of Arsenal Foot Plating System, expands offerings to address both tri-malleolar and intra-articular fracture patterns DJO® is now part of the Enovis™ family.* Enovis Corporation, an inno...
Diamond Hill invests on behalf of clients through a shared commitment to its valuation-driven investment principles, long-term perspective, capacity discipline and client alignment. Amid a rocky market quarter overall, Diamond Hill Mid Cap Fund's negative returns still outpaced the Ru...
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 15:15:06 ET Needham analyst issues BUY recommendation for ENOV on July 2, 2024 01:01PM ET. The previous analyst recommendation was Buy. ENOV was trading at $44.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst ...
2024-07-02 09:00:08 ET Vijay Kumar from Evercore ISI issued a price target of $62.00 for ENOV on 2024-07-02 08:02:00. The adjusted price target was set to $62.00. At the time of the announcement, ENOV was trading at $44.35. The overall price target consensus is at $67.00...
Wilmington, DE, May 10, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Bank of America Healthcare Conference: Ben ...